Crossbeta gains new ceo and funding

Dutch biotech to advance technology in several therapeutic areas

Crossbeta Biosciences, based in Utrecht in The Netherlands has appointed Guus Scheefhals as chief executive.

Scheefhals has joined the biotech firm from Avantium, where he held several managerial positions, most recently as chief operating officer of the pharma business unit. Prior to Avantium, he held commercial positions at DSM Biologics, Analytico and NPBI, which is now part of Fresenius.

Scheefhals replaces Johan Renes, who steps down after being with the company from the start and for the past two years as part-time ceo.

Crossbeta has recently won funding of €2m, which will be used to advance the firm’s technology in several therapeutic areas and to establish a stronger position for co-development programmes and commercialisation partnerships.

You may also like

Research & Development

Probiodrug and Crossbeta Biosciences enter into a partnership in the field of Alzheimer’s disease biomarkers

Licensing and supply agreement is based on Crossbeta’s proprietary technology and supports Probiodrug’s biomarker development activities
Research & Development

From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater

A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Pharmaceutical

Ardena strengthens executive team to drive its next phase of growth

Ghent, Belgium, 4 May 2026 – Ardena, a specialist pharmaceutical CDMO and bioanalytical CRO enabling precision medicines and other complex therapies, announces the appointments of Ben Ash as Chief Financial Officer and Henny Zijlstra as Chief Commercial Officer. These additions further strengthen Ardena’s executive leadership team as the company continues to scale its operations and commercial reach globally
Drug Delivery

Neuland Laboratories to partner with LIR Life Sciences for transdermal GLP-1 development

The pair will work to advance LIR Life's novel cell-penetrating peptides for next-generation obesity therapies, looking to improve patient adherence and broaden access
Pharmaceutical

Backed by investments exceeding $1 billion, PCI Pharma Services announces major expansion of US sterile fill-finish and drug-device delivery combination capabilities

As pharma manufacturers prioritise US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging
Manufacturing

New Romaco Maximus 400 tablet coater at interpack

Ideal for pharmaceutical coatings with a very large weight gain
Subscribe now